ProfileGDS5678 / 1443927_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 53% 55% 54% 54% 59% 55% 56% 54% 51% 55% 54% 57% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4624456
GSM967853U87-EV human glioblastoma xenograft - Control 23.3128153
GSM967854U87-EV human glioblastoma xenograft - Control 33.3635555
GSM967855U87-EV human glioblastoma xenograft - Control 43.2638354
GSM967856U87-EV human glioblastoma xenograft - Control 53.2745254
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6138859
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4542255
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3954456
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3198854
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.203651
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3526655
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2950154
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4574157
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3613655